314 related articles for article (PubMed ID: 25290419)
21. Does allergen immunotherapy alter the natural course of allergic disorders?
Yang X
Drugs; 2001; 61(3):365-74. PubMed ID: 11293647
[TBL] [Abstract][Full Text] [Related]
22. [Immunotherapy of allergic diseases: present and future].
Müller U
Schweiz Med Wochenschr; 1983 Dec; 113(52):1982-8. PubMed ID: 6229874
[TBL] [Abstract][Full Text] [Related]
23. New strategies for allergen immunotherapy.
Carnés J; Robinson DS
Recent Pat Inflamm Allergy Drug Discov; 2008 Jun; 2(2):92-101. PubMed ID: 19075996
[TBL] [Abstract][Full Text] [Related]
24. [Effector cells in allergy: biological principles and new pharmacologic concepts].
Sperr WR; Agis H; Valenta R; Bankl HC; Sillaber C; Scheiner O; Kraft D; Lechner K; Valent P
Wien Klin Wochenschr; 1993; 105(23):677-81. PubMed ID: 7508662
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of allergen-specific immunotherapy and novel ways for vaccine development.
Jutel M; Van de Veen W; Agache I; Azkur KA; Akdis M; Akdis CA
Allergol Int; 2013 Dec; 62(4):425-33. PubMed ID: 24153333
[TBL] [Abstract][Full Text] [Related]
26. Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy.
Takai T; Yokota T; Yasue M; Nishiyama C; Yuuki T; Mori A; Okudaira H; Okumura Y
Nat Biotechnol; 1997 Aug; 15(8):754-8. PubMed ID: 9255789
[TBL] [Abstract][Full Text] [Related]
27. Linking allergy to autoimmune disease.
Valenta R; Mittermann I; Werfel T; Garn H; Renz H
Trends Immunol; 2009 Mar; 30(3):109-16. PubMed ID: 19231288
[TBL] [Abstract][Full Text] [Related]
28. [Specific and nonspecific (anti-IgE) immunotherapy of allergic diseases].
Pichler WJ
Ther Umsch; 2001 May; 58(5):329-36. PubMed ID: 11407237
[TBL] [Abstract][Full Text] [Related]
29. Increase in allergen-specific IgE and ex vivo Th2 responses after a single bronchial challenge with house dust mite in allergic asthmatics.
van de Pol MA; Lutter R; van Ree R; van der Zee JS
Allergy; 2012 Jan; 67(1):67-73. PubMed ID: 21958117
[TBL] [Abstract][Full Text] [Related]
30. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.
Senti G; Johansen P; Haug S; Bull C; Gottschaller C; Müller P; Pfister T; Maurer P; Bachmann MF; Graf N; Kündig TM
Clin Exp Allergy; 2009 Apr; 39(4):562-70. PubMed ID: 19226280
[TBL] [Abstract][Full Text] [Related]
31. Review on immunotherapy in airway allergen sensitised patients.
van der Valk JP; de Jong NW; Gerth van Wijk R
Neth J Med; 2015 Jul; 73(6):263-9. PubMed ID: 26228190
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of allergic inflammation in the lung by plasmid DNA allergen immunization.
Spiegelberg HL; Broide D; Tighe H; Roman M; Raz E
Pediatr Pulmonol Suppl; 1999; 18():118-21. PubMed ID: 10093118
[TBL] [Abstract][Full Text] [Related]
33. Allergen-specific IgE in circulating immune complexes in patients with inhalant allergy undergoing specific immunotherapy.
Rogala B; Glück J
J Investig Allergol Clin Immunol; 1999; 9(3):183-9. PubMed ID: 10412681
[TBL] [Abstract][Full Text] [Related]
34. Profound reduction in allergen sensitivity following treatment with a novel allergy vaccine.
Hellman L
Eur J Immunol; 1994 Feb; 24(2):415-20. PubMed ID: 8299691
[TBL] [Abstract][Full Text] [Related]
35. Mast cells and IgE in defense against venoms: Possible "good side" of allergy?
Galli SJ; Starkl P; Marichal T; Tsai M
Allergol Int; 2016 Jan; 65(1):3-15. PubMed ID: 26666482
[TBL] [Abstract][Full Text] [Related]
36. Long-term effects: Galectin-1 and specific immunotherapy for allergic responses in the intestine.
Yang LT; Shu Q; Luo XQ; Liu ZQ; Qiu SQ; Liu JQ; Guo HJ; Li LJ; Li MG; Liu DB; Xia LX; Liu ZG; Yang PC
Allergy; 2018 Jan; 73(1):106-114. PubMed ID: 28718965
[TBL] [Abstract][Full Text] [Related]
37. Regulation of type 2 immunity by basophils.
Voehringer D
Adv Exp Med Biol; 2013; 785():37-41. PubMed ID: 23456835
[TBL] [Abstract][Full Text] [Related]
38. Functions of dendritic-cell-bound IgE in allergy.
Platzer B; Stout M; Fiebiger E
Mol Immunol; 2015 Dec; 68(2 Pt A):116-9. PubMed ID: 26052071
[TBL] [Abstract][Full Text] [Related]
39. Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen.
Hochreiter R; Stepanoska T; Ferreira F; Valenta R; Vrtala S; Thalhamer J; Hartl A
Eur J Immunol; 2003 Jun; 33(6):1667-76. PubMed ID: 12778485
[TBL] [Abstract][Full Text] [Related]
40. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis.
Rossi RE; Monasterolo G; Coco G; Operti D
Int Arch Allergy Immunol; 2005 Oct; 138(2):105-10. PubMed ID: 16174987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
